Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kyle Bennett

Internal Medicine Greenville, SC Medical Doctor

NPI 1740623115 CMS profile 1266473

50 Cross Park Ct, Greenville, SC 29605

Open in the dashboard

General payments

$1,479

72 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Bennett of Greenville, SC is reported in the CMS Open Payments database as having received $1,479 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $592 30
2024 General $699 31
2023 General $164 10
2022 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Bennett
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kyle Bennett were reported at $592. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kyle Bennett Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $24 $141 $42–$496 $149
2023 $164 $149 $45–$519 $160
2024 $699 $154 $47–$537 $164
2025 $592 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $591 30 payments
  2. Novo Nordisk Inc $200 12 payments
  3. Exact Sciences Corporation $120 8 payments
  4. Otsuka America Pharmaceutical, Inc. $109 1 payment
  5. Dexcom, Inc. $70 4 payments
  6. Inspire Medical Systems, Inc. $67 1 payment
  7. Amgen Inc. $58 4 payments
  8. Astellas Pharma US Inc $56 2 payments
  9. Merck Sharp & Dohme Corporation $49 2 payments
  10. Esperion Therapeutics, Inc. $43 2 payments
  11. Other $115 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,479 72 payments
Products named General payments · program years 2022–2025
  1. ZEPBOUND $310 13 payments
  2. MOUNJARO $258 17 payments
  3. RYBELSUS $113 6 payments
  4. Ozempic $113 6 payments
  5. REXULTI $109 1 payment
  6. Tresiba $99 5 payments
  7. Dexcom G6 Transmitter $70 4 payments
  8. INSPIRE $67 1 payment
  9. JARDIANCE $66 3 payments
  10. Cologuard Collection Kit $64 4 payments
  11. Other $493 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

5,094

Median for Hospitalist: 109

Drug cost

$342,937

Median for Hospitalist: $6,399

Branded share of claims

19.6%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 88 $90,970
Ozempic Semaglutide Brand 44 $63,183
Mounjaro Tirzepatide Brand 37 $59,197
Jardiance Empagliflozin Brand 16 $20,715
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $14,959
Trulicity Dulaglutide Brand 13 $13,695
Repatha Sureclick Evolocumab Brand 13 $11,600
Symbicort Budesonide/Formoterol Fumarate Brand 17 $4,511
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 23 $3,907
Novolog Flexpen Insulin Aspart Brand 11 $3,858

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$107,243

Of which drugs: $3,315

Medicare patients

234

Average age 73

Services billed

2,291

121 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 33%
Ischemic heart disease 33%
Depression 26%
Chronic kidney disease 25%
Heart failure 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 19 20 $1,607

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $193
$193 — —
MOUNJARO
  • Lilly USA, LLC $112
$112 37 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $109
$109 — —
Veozah
  • Astellas Pharma US Inc $28
$28 — —
RYBELSUS
  • Novo Nordisk Inc $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record